Encephalitis, Japanese
A mosquito-borne encephalitis caused by the Japanese B encephalitis virus (ENCEPHALITIS VIRUS, JAPANESE) occurring throughout Eastern Asia and Australia. The majority of infections occur in children and are subclinical or have features limited to transient fever and gastrointestinal symptoms. Inflammation of the brain, spinal cord, and meninges may occur and lead to transient or permanent neurologic deficits (including a POLIOMYELITIS-like presentation); SEIZURES; COMA; and death. (From Adams et al., Principles of Neurology, 6th ed, p751; Lancet 1998 Apr 11;351(9109):1094-7)
Drugs by status
Approved for this indication (3)
Phase 4 trials (4)
Phase 3 trials (7)
Organizations
Organization Involved with Phase 4 Indications (19)
- Valneva
- Sanofi
- Sanofi-Aventis
- Changchun Keygen Biological Products Co., Ltd.
- INC Research
- Centers for Disease Control and Prevention, China
- National Institute of Mental Health and Neuro Sciences, India
- Indian Institute of Science
- University of Liverpool
- University of Vienna
- International Center for Diarrheal Disease Research
- Boryung Pharmaceutical Company
- Medical University of Vienna
- Government of China
- Wellcome Trust
- KhonKaen University
- Centers for Disease Control and Prevention (CDC)
- PATH
- DF/Net Research
Organization Involved with Phase 3 Indications (24)
- Novartis
- Swedish Institute for Infectious Disease Control
- University of London
- Gachon University
- Inje University
- Korea Cancer Center Hospital
- Kyung Hee University
- Mahidol University
- Seoul National University
- Vince & Associates
- Karolinska Institute
- Wonju Christian Hospital
- Catholic University of Korea
- Ewha Womans University
- Inha University
- Sri Lanka Ministry of Healthcare and Nutrition
- Heart of America Research Institute
- Shandong Hengye Biotech Co., Ltd.
- Government of Vietnam
- Sungkyunkwan University
- Population Services International
- University of Helsinki
- Chinese Academy of Medical Sciences
- Inner Mongolia Autonomous Region Center for Diseases Prevention and Control (IMCDC)
Organization Involved with Phase 2 Indications (10)
- Azad University
- Duke University
- Indian Council of Medical Research
- King George's Medical University
- Singapore General Hospital
- B.P. Koirala Institute of Health Sciences
- Pharmaceutical Research Associates, Inc. (PRA)
- Government Medical College, Baroda, India
- Dr Atul's Child Hospital, Jaipur
- Kanti Children's Hospital
Organization Involved with Other Experimental Indications (1)